3 news items
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
9 Apr 24
and uncertainties that could cause the company's development programs, future results, performance or achievements to differ materially from those
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation
- Prev
- 1
- Next